Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeGet StartedBook a Demo
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

IMPACT Therapeutics and Pharmanovia Form Partnership to Commercialize Senaparib in 66 Countries.

Aug 02, 2026•7 days ago

Contract Type

partnership

ShanghaiBiotechnologyHealth CareScience And Engineering

Description

IMPACT Therapeutics has entered an exclusive partnership with Pharmanovia to commercialize Senaparib for advanced ovarian cancer across Europe, MENA, Australia, and New Zealand. The partnership includes a licensing agreement worth up to EUR423.5 million, allowing Pharmanovia to manufacture and develop the drug in these regions.

Company Information

Company

IMPACT Therapeutics

Location

Shanghai, Shanghai, China

About

IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. IMPACT Therapeutics has assembled one of the most comprehensive DNA damage response (DDR) global pipelines of novel drug candidates generated by in-house discovery efforts and is expanding to other novel synthetic lethality targets to broaden its pipeline. IMPACT pipeline products include PARP inhibitor (Senaparib/ IMP4297), Wee1 inhibitor (IMP7068), ATR inhibitor (IMP9064) and other novel DDR pathway inhibitors. The lead clinical program, PARP inhibitor (Senaparib/ IMP4297), is in Phase II/III studies for ovarian cancer, prostate cancer, small cell lung cancer and other indications worldwide, including China. Senaparib's preliminary clinical data demonstrated superior tolerability and wider therapeutic windows compared with other PARPi. Phase I study of Wee1 inhibitor (IMP7068) is conducted globally. ATR Inhibitor IMP9064 has received IND Clearance by the FDA to start clinical studies in the U.S. and submitted clinical application in China. Hedgehog pathway inhibitor (IMP5471) has received IND approval from NMPA to initiate clinical studies in China. For more information, please visit www.impacttherapeutics.com/en/.

Predictive Intelligence
Strategic

ML-powered predictions for IMPACT Therapeutics's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.